Supriya Lifescience Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Supriya Lifescience Limited reported strong audited results for the year ended March 31, 2025. Revenue from operations grew 22.1% year-on-year to Rs. 6,964.85 million, while profit after tax surged 57.8% to Rs. 1,879.58 million. EPS stood at Rs. 23.35 versus Rs. 14.80 in the previous year. The Board recommended a final dividend of Re. 1.00 per share (50% on face value of Rs. 2), subject to shareholder approval. Statutory auditor Kakaria & Associates LLP issued an unmodified opinion on the results. The company also appointed M/s. DSM & Associates as Secretarial Auditors for a five-year term starting FY 2025-26.
This is a strong set of results for shareholders — both top-line growth and bottom-line expansion are well above industry norms, and the company remains debt-free with a healthy equity base of nearly Rs. 10,000 million. The dividend announcement rewards investors, and the clean audit opinion signals good financial governance.